{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:14:19Z","timestamp":1759961659101,"version":"3.37.3"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100008386","name":"Marmara \u00dcniversitesi","doi-asserted-by":"publisher","award":["SAG-C-DRP-131015-0436"],"award-info":[{"award-number":["SAG-C-DRP-131015-0436"]}],"id":[{"id":"10.13039\/501100008386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1111\/jcpt.12814","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T18:00:17Z","timestamp":1550167217000},"page":"553-560","source":"Crossref","is-referenced-by-count":14,"title":["Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study"],"prefix":"10.1155","volume":"44","author":[{"given":"Volkan","family":"Aydin","sequence":"first","affiliation":[{"name":"Department of Pharmacology; Marmara University School of Medicine; Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8593-0818","authenticated-orcid":false,"given":"Ahmet","family":"Akici","sequence":"additional","affiliation":[{"name":"Department of Pharmacology; Marmara University School of Medicine; Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Isli","sequence":"additional","affiliation":[{"name":"Turkish Medicines and Medical Devices Agency; Ministry of Health; Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mesil","family":"Aksoy","sequence":"additional","affiliation":[{"name":"Turkish Medicines and Medical Devices Agency; Ministry of Health; Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehtap","family":"Aydin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology; Baskent University School of Medicine; Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakki","family":"Gursoz","sequence":"additional","affiliation":[{"name":"Turkish Medicines and Medical Devices Agency; Ministry of Health; Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"10.1111\/jcpt.12814-BIB0001|jcpt12814-cit-0001","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2249.2010.04146.x","article-title":"How tumour necrosis factor blockers interfere with tuberculosis immunity","volume":"161","author":"Harris","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/jcpt.12814-BIB0002|jcpt12814-cit-0002","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2174\/156802606778194217","article-title":"Anti-TNF-alpha antibody therapies in autoimmune diseases","volume":"6","author":"Chatzantoni","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"10.1111\/jcpt.12814-BIB0003|jcpt12814-cit-0003","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents - comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"key":"10.1111\/jcpt.12814-BIB0004|jcpt12814-cit-0004","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","article-title":"Inhibitory effect of TNF\u03b1 antibodies on synovial cell interleukin-1 production in rheumatoid arthritis","volume":"334","author":"Brennan","year":"1989","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12814-BIB0005|jcpt12814-cit-0005","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","article-title":"Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey","volume":"119","author":"Aggarwal","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jcpt.12814-BIB0006|jcpt12814-cit-0006","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.trsl.2014.09.006","article-title":"Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases","volume":"165","author":"Willrich","year":"2015","journal-title":"Transl Res"},{"key":"10.1111\/jcpt.12814-BIB0007|jcpt12814-cit-0007","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1086\/429998","article-title":"Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?","volume":"41","author":"Ehlers","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/jcpt.12814-BIB0008|jcpt12814-cit-0008","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jcpt.12814-BIB0009|jcpt12814-cit-0009","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jcpt.12814-BIB0010|jcpt12814-cit-0010","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"G\u00f3mez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jcpt.12814-BIB0011|jcpt12814-cit-0011","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jcpt.12814-BIB0012|jcpt12814-cit-0012","first-page":"S47","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance","volume":"41","author":"Cantini","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1111\/jcpt.12814-BIB0013|jcpt12814-cit-0013","doi-asserted-by":"crossref","first-page":"e012567","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"key":"10.1111\/jcpt.12814-BIB0014|jcpt12814-cit-0014","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1111\/jcpt.12814-BIB0015|jcpt12814-cit-0015","first-page":"553","article-title":"Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment","volume":"59","author":"Nordgaard-Lassen","year":"2012","journal-title":"Dan Med J"},{"key":"10.1111\/jcpt.12814-BIB0016|jcpt12814-cit-0016","first-page":"49","article-title":"Treatment with tumor necrosis factor-alpha antagonists and infections","volume":"3","author":"Kalfa","year":"2011","journal-title":"RAED J"},{"key":"10.1111\/jcpt.12814-BIB0017|jcpt12814-cit-0017","unstructured":"Sa\u011fl\u0131k TC Bakanl\u0131\u011f\u0131 \u0130la\u00e7 ve Eczac\u0131l\u0131k Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc. TNF-\u03b1 blokerleri hakk\u0131nda 149\/2005 say\u0131l\u0131 genelge [General Directorate of Drug and Pharmacy of Turkish Ministry of Health, circular on TNF-\u03b1 inhibitors, numbered 149\/2005] 2005"},{"volume-title":"Tuberculosis Surveillance and Monitoring in Europe 2017","year":"2017","author":"European Centre for Disease Prevention and Control\/WHO Regional Office for Europe","key":"10.1111\/jcpt.12814-BIB0018|jcpt12814-cit-0018"},{"key":"10.1111\/jcpt.12814-BIB0019|jcpt12814-cit-0019","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.rmed.2013.09.011","article-title":"Effects of the health transformation programme on tuberculosis burden in Turkey","volume":"107","author":"Yildirim","year":"2013","journal-title":"Respir Med"},{"key":"10.1111\/jcpt.12814-BIB0020|jcpt12814-cit-0020","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10067-008-0867-3","article-title":"The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients","volume":"27","author":"Hanta","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1111\/jcpt.12814-BIB0021|jcpt12814-cit-0021","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10067-008-1067-x","article-title":"Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha","volume":"28","author":"Elbek","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1111\/jcpt.12814-BIB0022|jcpt12814-cit-0022","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5152\/ttd.2012.22","article-title":"Tuberculosis frequency in patients taking TNF-alpha blockers","volume":"13","author":"Dogan","year":"2012","journal-title":"Turk Toraks Derg"},{"key":"10.1111\/jcpt.12814-BIB0023|jcpt12814-cit-0023","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3899\/jrheum.150177","article-title":"Characteristics predicting tuberculosis risk under tumor necrosis factor-\u03b1 inhibitors: report from a large multicenter cohort with high background prevalence","volume":"43","author":"Kisacik","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1111\/jcpt.12814-BIB0024|jcpt12814-cit-0024","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000434684","article-title":"Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-a treatment","volume":"90","author":"Borekci","year":"2015","journal-title":"Respiration"},{"key":"10.1111\/jcpt.12814-BIB0025|jcpt12814-cit-0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1546-0096-12-45","article-title":"Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-\u03b1 reagents","volume":"12","author":"Yasui","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1111\/jcpt.12814-BIB0026|jcpt12814-cit-0026","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1111\/jcpt.12814-BIB0027|jcpt12814-cit-0027","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/ard.2005.047274","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan","volume":"65","author":"Yamada","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/jcpt.12814-BIB0028|jcpt12814-cit-0028","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"volume-title":"Global Tuberculosis Report 2017","year":"2017","author":"WHO","key":"10.1111\/jcpt.12814-BIB0029|jcpt12814-cit-0029"},{"key":"10.1111\/jcpt.12814-BIB0030|jcpt12814-cit-0030","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3899\/jrheum.150057","article-title":"The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-\u03b1 antagonist: a metaanalysis of both randomized controlled trials and registry\/cohort studies","volume":"42","author":"Ai","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1111\/jcpt.12814-BIB0031|jcpt12814-cit-0031","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/annrheumdis-2013-204960","article-title":"Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?","volume":"74","author":"Arkema","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/jcpt.12814-BIB0032|jcpt12814-cit-0032","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/ajrccm.158.2.9709125","article-title":"Long-term trends in tuberculosis: comparison of age-cohort data between Hong Kong and England and Wales","volume":"158","author":"Tocque","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/jcpt.12814-BIB0033|jcpt12814-cit-0033","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/jcpt.12644","article-title":"Risk of tuberculosis comparison in new users of antitumour necrosis factor-\u03b1 and with existing disease-modifying antirheumatic drug therapy","volume":"43","author":"Chan","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/jcpt.12814-BIB0034|jcpt12814-cit-0034","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40121-013-0003-9","article-title":"Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review","volume":"2","author":"Solovan","year":"2013","journal-title":"Infect Dis Ther"},{"key":"10.1111\/jcpt.12814-BIB0035|jcpt12814-cit-0035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10067-014-2536-z","article-title":"The use of TNF-\u03b1 blockers in psoriatic arthritis patients with latent tuberculosis infection","volume":"33","author":"Atteno","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1111\/jcpt.12814-BIB0036|jcpt12814-cit-0036","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2340\/00015555-1106","article-title":"Patients with psoriasis are more likely to be treated for latent tuberculosis infection prior to biologics than patients with inflammatory bowel disease","volume":"91","author":"Bassukas","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/jcpt.12814-BIB0037|jcpt12814-cit-0037","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000222431","article-title":"Tuberculin skin test overestimates tuberculosis hypersensitivity in adult patients with psoriasis","volume":"219","author":"Tsiouri","year":"2009","journal-title":"Dermatology"},{"key":"10.1111\/jcpt.12814-BIB0038|jcpt12814-cit-0038","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.24476","article-title":"Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada","volume":"61","author":"Brassard","year":"2009","journal-title":"Arthritis Care Res"},{"key":"10.1111\/jcpt.12814-BIB0039|jcpt12814-cit-0039","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","article-title":"Antirheumatic drugs and the risk of tuberculosis","volume":"43","author":"Brassard","year":"2006","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12814","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12814\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:04:14Z","timestamp":1671818654000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,14]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12814","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"type":"print","value":"0269-4727"}],"subject":[],"published":{"date-parts":[[2019,2,14]]}}}